



## Caribou Biosciences to Participate in Upcoming Investor Conferences

August 26, 2024

BERKELEY, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- [Caribou Biosciences, Inc.](#) (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced company leadership will participate in the following event and investor conferences:

- **Morgan Stanley 22nd Annual Global Healthcare Conference**, New York, NY  
September 4, 2024
- **2024 Wells Fargo Healthcare Conference**, Boston, MA  
September 5, 2024

During these conferences, Caribou leadership will conduct one-on-one meetings with investors registered. For more information, visit the [Events](#) page on Caribou's website.

### **About Caribou's novel next-generation CRISPR platform**

CRISPR genome editing uses easily designed, modular biological tools to make DNA changes in living cells. There are two basic components of Class 2 CRISPR systems: the nuclease protein that cuts DNA and the RNA molecule(s) that guide the nuclease to generate a site-specific, double-stranded break, leading to an edit at the targeted genomic site. CRISPR systems are capable of editing unintended genomic sites, known as off-target editing, which may lead to harmful effects on cellular function and phenotype. In response to this challenge, Caribou has developed CRISPR hybrid RNA-DNA guides (chRDNA; pronounced "chardonnays") that direct substantially more precise genome editing compared to all-RNA guides. Caribou is deploying the power of its Cas12a chRDNA technology to carry out high efficiency multiple edits, including multiplex gene insertions, to develop CRISPR-edited therapies.

### **About Caribou Biosciences, Inc.**

Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company's genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against disease. Caribou is advancing a pipeline of off-the-shelf cell therapies from its CAR-T platform as readily available treatments for patients with hematologic malignancies and autoimmune diseases. Follow us [@CaribouBio](#) and visit [www.cariboubio.com](http://www.cariboubio.com).

### **Caribou Biosciences, Inc. contacts:**

Investors:

Amy Figueroa, CFA  
[investor.relations@cariboubio.com](mailto:investor.relations@cariboubio.com)

Media:

Peggy Vorwald, PhD  
[media@cariboubio.com](mailto:media@cariboubio.com)